Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an announcement.
Sihuan Pharmaceutical Holdings Group has announced the completion of the first patient enrollment in a Phase III clinical trial for Anaprazole Sodium Enteric Coated Tablets, targeting reflux esophagitis. This development marks an expansion of indications for the drug, which is the first and only fully independently developed proton pump inhibitor (PPI) in China. The trial, involving multiple leading medical institutions, aims to evaluate the drug’s efficacy and safety, potentially broadening its market reach and creating commercial synergies. The growing prevalence of reflux esophagitis and peptic ulcers in China, combined with the drug’s unique properties, positions it for significant clinical and commercial success.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, through its subsidiary XuanZhu BioPharm, operates in the pharmaceutical industry with a focus on innovative drug development. The company specializes in treatments for major diseases such as digestion, oncology, and non-alcoholic steatohepatitis, leveraging its expertise in small molecule chemistry and large molecule biologics to develop proprietary drugs.
Average Trading Volume: 130,778,141
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.69B
See more insights into 0460 stock on TipRanks’ Stock Analysis page.